- Home
- CCCC vs ACRS Comparison
CCCC vs ACRS Comparison
Compare CCCC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- ACRS
- Stock Information
- Founded
- CCCC 2015
- ACRS 2012
- Country
- CCCC United States
- ACRS United States
- Employees
- CCCC N/A
- ACRS N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- ACRS Health Care
- Exchange
- CCCC Nasdaq
- ACRS Nasdaq
- Market Cap
- CCCC 115.0M
- ACRS 137.5M
- IPO Year
- CCCC 2020
- ACRS 2015
- Fundamental
- Price
- CCCC $1.47
- ACRS $1.56
- Analyst Decision
- CCCC Buy
- ACRS Strong Buy
- Analyst Count
- CCCC 3
- ACRS 8
- Target Price
- CCCC $12.00
- ACRS $9.71
- AVG Volume (30 Days)
- CCCC 943.9K
- ACRS 735.3K
- Earning Date
- CCCC 07-31-2025
- ACRS 05-08-2025
- Dividend Yield
- CCCC N/A
- ACRS N/A
- EPS Growth
- CCCC N/A
- ACRS N/A
- EPS
- CCCC N/A
- ACRS N/A
- Revenue
- CCCC $39,783,000.00
- ACRS $17,777,000.00
- Revenue This Year
- CCCC N/A
- ACRS N/A
- Revenue Next Year
- CCCC N/A
- ACRS $11.66
- P/E Ratio
- CCCC N/A
- ACRS N/A
- Revenue Growth
- CCCC 98.56
- ACRS N/A
- 52 Week Low
- CCCC $1.09
- ACRS $0.99
- 52 Week High
- CCCC $7.66
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CCCC 51.01
- ACRS 64.23
- Support Level
- CCCC $1.21
- ACRS $1.22
- Resistance Level
- CCCC $1.57
- ACRS $1.65
- Average True Range (ATR)
- CCCC 0.12
- ACRS 0.10
- MACD
- CCCC 0.02
- ACRS 0.04
- Stochastic Oscillator
- CCCC 70.27
- ACRS 80.85
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.